Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model.
BACKGROUND
Treatment strategies for the highly invasive brain tumor, glioblastoma multiforme, require that cells which have invaded into the surrounding brain be specifically targeted. The inherent tumor-tropism of neural stem cells (NSCs) to primary and invasive tumor foci can be exploited to deliver therapeutics to invasive brain tumor cells in humans. Use of the strategy of converting prodrug to drug via therapeutic transgenes delivered by immortalized therapeutic NSC lines have shown efficacy in animal models. Thus therapeutic NSCs are being proposed for use in human brain tumor clinical trials. In the context of NSC-based therapies, MRI can be used both to non-invasively follow dynamic spatio-temporal patterns of the NSC tumor targeting allowing for the optimization of treatment strategies and to assess efficacy of the therapy. Iron-labeling of cells allows their presence to be visualized and tracked by MRI. Thus we aimed to iron-label therapeutic NSCs without affecting their cellular physiology using a method likely to gain United States Federal Drug Administration (FDA) approval.


METHODS
For human use, the characteristics of therapeutic Neural Stem Cells must be clearly defined with any pertubation to the cell including iron labeling requiring reanalysis of cellular physiology. Here, we studied the effect of iron-loading of the therapeutic NSCs, with ferumoxide-protamine sulfate complex (FE-Pro) on viability, proliferation, migratory properties and transgene expression, when compared to non-labeled cells. FE-Pro labeled NSCs were imaged by MRI at tumor sites, after intracranial administration into the hemisphere contralateral to the tumor, in an orthotopic human glioma xenograft mouse model.


CONCLUSIONS
FE-Pro labeled NSCs retain their proliferative status, tumor tropism, and maintain stem cell character, while allowing in vivo cellular MRI tracking at 7 Tesla, to monitor their real-time migration and distribution at brain tumor sites. Of significance, this work directly supports the use of FE-Pro-labeled NSCs for real-time tracking in the clinical trial under development: "A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically modified Neural Stem Cells Expressing Escherichia coli Cytosine Deaminase for Treatment of Recurrent High-Grade Gliomas".
Thu
Mya S
MS
Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, United States of America.
Najbauer
Joseph
J
Kendall
Stephen E
SE
Harutyunyan
Ira
I
Sangalang
Nicole
N
Gutova
Margarita
M
Metz
Marianne Z
MZ
Garcia
Elizabeth
E
Frank
Richard T
RT
Kim
Seung U
SU
Moats
Rex A
RA
Aboody
Karen S
KS
D000818:Animals; D001921:Brain / Q000378:metabolism; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology*; D003911:Dextrans; D004195:Disease Models, Animal; D052203:Ferrosoferric Oxide / Q000737:chemistry; D005910:Glioma / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007501:Iron / Q000378:metabolism*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D051379:Mice; D009368:Neoplasm Transplantation; D009474:Neurons / Q000166:cytology*; D011479:Protamines / Q000737:chemistry; D013234:Stem Cells / Q000166:cytology*
D003911:Dextrans; D058185:Magnetite Nanoparticles; D011479:Protamines; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide